Sargent Bickham Lagudis’s Sage Therapeutics SAGE Stock Holding History

Sargent Bickham Lagudis’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-85	Closed	-$5K	–	977
2021 Q2	$5K	Hold	85	–	–	﹤0.01%	803
2021 Q1	$6K	Hold	85	–	–	﹤0.01%	777
2020 Q4	$7K	Hold	85	–	–	﹤0.01%	704
2020 Q3	$5K	Hold	85	–	–	﹤0.01%	667
2020 Q2	$4K	Hold	85	–	–	﹤0.01%	668
2020 Q1	$2K	Hold	85	–	–	﹤0.01%	714
2019 Q4	$6K	Hold	85	–	–	﹤0.01%	675
2019 Q3	$12K	Hold	85	–	–	﹤0.01%	542
2019 Q2	$16K	Hold	85	–	–	﹤0.01%	535
2019 Q1	$14K	Hold	85	–	–	﹤0.01%	567
2018 Q4	$8K	Hold	85	–	–	﹤0.01%	613
2018 Q3	$12K	Hold	85	–	–	﹤0.01%	587
2018 Q2	$13K	Hold	85	–	–	﹤0.01%	548
2018 Q1	$14K	Hold	85	–	–	﹤0.01%	532
2017 Q4	$14K	Hold	85	–	–	﹤0.01%	554
2017 Q3	$5K	Hold	85	–	–	﹤0.01%	698
2017 Q2	$7K	Hold	85	–	–	﹤0.01%	626
2017 Q1	$6K	Hold	85	–	–	﹤0.01%	646
2016 Q4	$4K	Hold	85	–	–	﹤0.01%	641
2016 Q3	$4K	Hold	85	–	–	﹤0.01%	661
2016 Q2	$3K	Hold	85	–	–	﹤0.01%	652
2016 Q1	$3K	Buy	+85	New	+$2.99K	﹤0.01%	668

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sargent Bickham Lagudis's SAGE Position: Q3 2021 in Review

Sargent Bickham Lagudis sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 85 shares — an estimated $5K sold.

Sargent Bickham Lagudis first reported a position in SAGE in Q1 2016 and held it in 22 quarters. The position peaked at $16K in Q2 2019. 226 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

Sargent Bickham Lagudis reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
Sargent Bickham Lagudis sold 85 Sage Therapeutics shares in Q3 2021, an estimated $5K.
Sargent Bickham Lagudis first reported a position in Sage Therapeutics in Q1 2016 and held it in 22 quarters.
Sargent Bickham Lagudis's Sage Therapeutics position peaked at $16K in Q2 2019.
226 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q3 2021, filed 5 Nov 2021.